<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Diabetes (type 1, 2, and gestational).&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Work Loss Data Institute. Diabetes (type 1, 2, and gestational). Encinitas (CA): Work Loss Data Institute; 2013 Sep 5. Various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Arthropathy associated with neurological disorders  (713.5); Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled  (250.01); Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled  (250.00); Hyperbaric oxygenation  (93.95); Loss of weight  (783.21); Screening for diabetes mellitus  (V77.1)"/><FieldValue Value="MSH: Anastomosis, Roux-en-Y ; Arthropathy, Neurogenic ; Bariatric Surgery ; Blood Glucose Self-Monitoring ; Braces ; Causality ; Coated Materials, Biocompatible ; Collagenases ; Debridement ; Diabetes Complications ; Diabetes Mellitus, Type 1 ; Diabetes Mellitus, Type 2 ; Diabetes, Gestational ; Diabetic Diet ; Diabetic Foot ; Diabetic Neuropathies ; Diabetic Retinopathy ; Diet Therapy ; Diet, Carbohydrate-Restricted ; Dietary Fiber ; Drug Delivery Systems ; Exercise ; Gastric Bypass ; Glucose Tolerance Test ; Hospitalization ; Hyperbaric Oxygenation ; Hypoglycemic Agents ; Insulin ; Insulin Lispro ; Ketogenic Diet ; Leeching ; Life Style ; Metformin ; Nutrition Therapy ; Occupational Diseases ; Occupational Health ; Office Visits ; Orthotic Devices ; Patient Education as Topic ; Prediabetic State ; Pregnancy ; Resistance Training ; Return to Work ; Risk Assessment ; Shoes ; Vision Tests ; Vitamin D ; Vitrectomy ; Weight Loss "/><FieldValue Value="MTH: Body Weight decreased ; Braces-Orthopedic appliances ; COLLAGENASE ; Complications of Diabetes Mellitus ; Debridement ; Debridement by Maggots ; Depression screen ; Diabetes Mellitus screen ; Diabetes Mellitus, Insulin-Dependent ; Diabetes Mellitus, Non-Insulin-Dependent ; Diabetic Diet ; Diabetic Foot ; Diabetic Neuropathies ; Diabetic Retinopathy ; Diet therapy ; Dietary Fiber ; Drug Delivery Systems ; Encounter for screening for diabetes mellitus ; Etiology ; Exercise ; Fit for work (finding) ; Fit for work with restrictions (finding) ; Gastric Bypass ; Gestational Diabetes ; Glucose Tolerance Test ; Hospitalization ; Hyperbaric oxygenation therapy ; Insulin ; Insulin Lispro ; Ketogenic Diet ; Leech Therapy ; Life Style ; Neurogenic arthropathy ; Nutrition Therapy ; Obesity screen ; occupational health specialty ; Orthotic Devices ; Patient education (procedure) ; Plasma Glucose Measurement ; Prediabetes syndrome ; Pregnancy ; Resistance Training ; Risk Assessment ; Roux-en-Y Anastomosis ; Screening for diabetes ; Vision Tests ; Vitamin D ; wound care "/><FieldValue Value="PDQ: insulin "/><FieldValue Value="SNOMEDCT_US: Abnormal glucose tolerance in mother complicating pregnancy, childbirth AND/OR puerperium  (39763004); Arthropathy associated with a neurological disorder  (359554008); Arthropathy associated with a neurological disorder  (67536000); Brace  (360316004); Bypass of stomach  (442338001); Carbohydrate restricted diet  (436691000124108); Carbohydrate restricted diet  (66539004); Collagenase product  (18394004); Collagenase product  (417416003); Debridement  (129317004); Debridement  (36777000); Depression screening  (171207006); Diabetes clinical management plan  (412777005); Diabetes mellitus screening  (171183004); Diabetes self-management behavior  (405096004); Diabetic complication  (74627003); Diabetic diet  (160670007); Diabetic foot  (280137006); Diabetic foot examination  (401191002); Diabetic neuropathic arthropathy  (201724008); Diabetic neuropathy  (230572002); Diabetic peripheral neuropathy screening  (401081006); Diabetic retinopathy  (4855003); Diabetic retinopathy screening  (134395001); Diabetic skin ulcer  (422183001); Dietary fiber  (116272000); Driving assessment  (310859004); Etiology  (134198009); Exenatide  (416859008); Exenatide  (417734003); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fit for work  (160926000); Fit for work with restrictions  (225891002); Fit to return to work  (302120006); Gestational diabetes mellitus  (11687002); Glucose measurement, plasma  (72191006); Glucose tolerance test  (113076002); Hyperbaric chamber  (91318002); Hyperbaric oxygen therapy  (18678000); Hypoglycemic agent  (312064005); Hypoglycemic agent  (373299009); Inpatient care  (394656005); Insulin  (39487003); Insulin  (412222002); Insulin  (67866001); Insulin pump  (69805005); Ketogenic diet  (226108007); Laparoscopic sleeve gastrectomy  (427074001); Life style  (134436002); Life style  (60134006); Lispro insulin  (388454007); Lispro insulin  (412210000); Low glycemic index food  (228043003); Metformin  (109081006); Metformin  (372567009); Nutrition therapy  (386373004); Obesity screening  (268551005); Occupational disorder  (115966001); Orthotic device  (224898003); Patient education  (311401005); Pregnancy  (289908002); Procedure using leeches  (225167009); Returned to work  (266962006); Risk assessment  (225338004); Roux-en-Y - action  (257747009); Screening for cardiovascular system disease  (300007000); Self-monitoring of blood glucose  (308113006); Shoes  (43983001); Sterile maggot wound debridement  (404916008); Treatment for hypertension started  (170586008); Type 1 diabetes mellitus  (46635009); Type 2 diabetes mellitus  (44054006); Visual testing  (268360001); Vitamin D  (11563006); Vitamin D  (30178006); Vitrectomy  (75732000); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005); Wound care  (225358003)"/><FieldValue Value="SPN: CHAMBER, HYPERBARIC ; PUMP, INFUSION, INSULIN "/><FieldValue Value="UMD: Chambers, Hyperbaric  (12-061); Infusion Pumps, Insulin  (28-074); Orthoses  (12-837); Shoes  (13-576)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;August 28, 2015 &amp;ndash; DPP-4 Inhibitors for Type 2 Diabetes&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Type 1 diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type 2 diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gestational diabetes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Gastroenterology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nutrition" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Ophthalmology" /><FieldValue Value="Podiatry" /><FieldValue Value="Preventive Medicine" /><FieldValue Value="Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Health Plans" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Utilization Management" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To offer evidence-based step-by-step decision protocols for the assessment and treatment of workers' compensation conditions&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Workers with type 1, type 2, and gestational diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following interventions/procedures were considered and recommended as indicated in the original guideline document:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bariatric surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular disease screening and treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Carpal tunnel syndrome (CTS): screening for diabetes in CTS patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Causation (determination) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Charcot arthropathy bracing and orthotics &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Collagenase ointment (wound healing) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Commercial drivers (fitness for duty) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depression screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dermagraft&amp;reg; (wound care) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic neuropathy (screening for) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic retinopathy (screening for) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic skin ulcers (screening and treatment) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diet (low-glycemic-index, low-carbohydrate) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dietary fiber &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Driving risk assessment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duodenum exclusion (in bariatric surgery) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exenatide (Byetta) as second-line treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fasting plasma glucose test (FPG) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Foot problems (screening for and appropriate footwear) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gastric bypass &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glucagon-like peptide-1 (GLP-1) agonists as second-line treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glucose monitoring (self-monitoring) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High-intensity interval training (HIIT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospital length of stay (LOS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperbaric oxygen therapy (HBOT) for diabetic skin ulcers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Humalog (insulin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insomnia screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insulin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insulin pump therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ketogenic diet &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Leech therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle (diet &amp;amp; exercise) modifications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-carbohydrate diet &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-glycemic-index diet &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maggot debridement therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Metabolic surgery (gastric bypass not gastric banding) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Metformin (Glucophage) as first-line treatment of type 2 diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;NovoLog (insulin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nutritional counseling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obesity (screening and concurrent treatment) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Office visits &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral glucose tolerance test (OGTT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Paleolithic diet &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prediabetes screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pre-filled insulin pen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psoriasis (accelerated diabetes screening and prevention in patients with psoriasis) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resistance training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Return to work &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Roux-en-Y gastric bypass &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sleeve gastrectomy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vision screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin D &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitrectomy (for diabetic retinopathy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weight-loss surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Wound care (diabetic foot ulcers) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Work/activity restrictions (specific accommodations requested by employees with diabetes) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The following interventions/procedures are under study and are not specifically recommended:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antiplatelet therapy (aspirin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ergonomics &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fracture comorbidity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lorcaserin (Belviq) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Manipulation under anesthesia (MUA) diabetes comorbidity (in adhesive capsulitis) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stem cell therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tasopoglutide &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The following interventions/procedures were considered, but are not recommended:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acarbose (Precose) as first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Alpha glucosidase inhibitors (AGIs) as first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Canagliflozin (Invokana) as first-line medication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Colesevelam as first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) as first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gastric banding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glimepiride (Amaryl) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glinides as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glipizide (Glucotrol) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glyburide (DiaBeta) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Humulin (insulin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lap band surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-fat diet &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Magnetic resonance imaging (MRIs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Meglitinide analogues as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Miglitol (Glyset) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monofilament testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nateglinide (Starlix) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Novolin (insulin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physical therapy (except for exercise training) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pramlintide as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Repaglinide (Prandin) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Saxagliptin (Onglyza) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sitagliptin (Januvia) as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Statins as a first-line treatment for diabetics &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sulfonylurea as a first-line choice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgery for Charcot arthropathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thiazolidinediones (TZDs) as a first-line choice &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of treatment in improving glycemic control and reducing complications of diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevalence and incidence of diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Predictive value of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk for developing diabetes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Loss Data Institute (WLDI) conducted a comprehensive medical literature review (now ongoing) with preference given to high quality systematic reviews, meta-analyses, and clinical trials published since 1993, plus existing nationally recognized treatment guidelines from the leading specialty societies. WLDI primarily searched MEDLINE and the Cochrane Library. In addition, WLDI also reviewed other relevant treatment guidelines, including those in the National Guideline Clearinghouse, as well as state guidelines and proprietary guidelines maintained in the WLDI guideline library. These guidelines were also used to suggest references or search terms that may otherwise have been missed. In addition, WLDI also searched other databases, including MD Consult, eMedicine, CINAHL, and conference proceedings in occupational health (i.e., American College of Occupational and Environmental Medicine [ACOEM]) and disability evaluation (i.e., American Academy of Disability Evaluating Physicians [AADEP], American Board of Independent Medical Examiners [ABIME]). Search terms and questions were diagnosis, treatment, symptom, sign, and/or body-part driven, generated based on new or previously indexed existing evidence, treatment parameters and experience.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In searching the medical literature, answers to the following questions were sought: (1) If the diagnostic criteria for a given condition have changed since 1993, what are the new diagnostic criteria? (2) What occupational exposures or activities are associated causally with the condition? (3) What are the most effective methods and approaches for the early identification and diagnosis of the condition? (4) What historical information, clinical examination findings or ancillary test results (such as laboratory or x-ray studies) are of value in determining whether a condition was caused by the patient's employment? (5) What are the most effective methods and approaches for treating the condition? (6) What are the specific indications, if any, for surgery as a means of treating the condition? (7) What are the relative benefits and harms of the various surgical and non-surgical interventions that may be used to treat the condition? (8) What is the relationship, if any, between a patient's age, gender, socioeconomic status and/or racial or ethnic grouping and specific treatment outcomes for the condition? (9) What instruments or techniques, if any, accurately assess functional limitations in an individual with the condition? (10) What is the natural history of the disorder? (11) Prior to treatment, what are the typical functional limitations for an individual with the condition? (12) Following treatment, what are the typical functional limitations for an individual with the condition? (13) Following treatment, what are the most cost-effective methods for preventing the recurrence of signs or symptoms of the condition, and how does this vary depending upon patient-specific matters such as underlying health problems?&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Criteria for Selecting the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Preference was given to evidence that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial &amp;ndash; randomized or controlled, or (4) The article reports a cohort study, whether prospective or retrospective, or (5) The article reports a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;More information about the selection of evidence is available in &quot;Appendix B. &lt;em&gt;ODG Treatment in Workers' Comp&lt;/em&gt;. Methodology description using the AGREE instrument&quot; (see &quot;the Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Ranking by Type of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Systematic Review/Meta-Analysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled Trial - Randomized (RCT) or Controlled &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cohort Study - Prospective or Retrospective &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Case Control Series &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Unstructured Review &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nationally Recognized Treatment Guideline (from &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC web site&quot; target=&quot;_blank&quot;&gt;www.guideline.gov&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;State Treatment Guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other Treatment Guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Textbook &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conference Proceedings/Presentation Slides &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ranking by Quality within Type of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;High Quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medium Quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low Quality &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Loss Data Institute (WLDI) reviewed each article that was relevant to answering the question at issue, with priority given to those that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial &amp;ndash; randomized or controlled, or (4) The article reported a cohort study, whether prospective or retrospective, or (5) The article reported a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Especially when articles on a specific topic that met the above criteria were limited in number and quality, WLDI also reviewed other articles that did not meet the above criteria, but all evidence was ranked alphanumerically (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field) so that the quality of evidence could be clearly determined when making decisions about what to recommend in the Guidelines. Articles with a Ranking by Type of Evidence of Case Reports and Case Series were not used in the evidence base for the Guidelines. These articles were not included because of their low quality (i.e., they tend to be anecdotal descriptions of what happened with no attempt to control for variables that might affect outcome). Not all the evidence provided by WLDI was eventually listed in the bibliography of the published Guidelines. Only the higher quality references were listed. The criteria for inclusion was a final ranking of 1a to 4b (the original inclusion criteria suggested the methodology subgroup), or if the Ranking by Type of Evidence was 5 to 10, the quality ranking should be an &quot;a.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Prior to publication, select organizations and individuals making up a cross-section of medical specialties and typical end-users externally reviewed the guideline. Complimentary review access is also made available to all major medical specialty groups as well as other stakeholders.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the Work Loss Data Institute (WLDI) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The following recommendations were current as of September 5, 2013. However, because the Work Loss Data Institute updates their guidelines frequently, users may wish to consult the &lt;a href=&quot;http://www.disabilitydurations.com/&quot; title=&quot;WLDI Web site&quot;&gt;WLDI Web site&lt;/a&gt; for the most current version available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pre-diagnosis (Pre-diabetes)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Blood glucose levels that are higher than normal but not high enough for a diagnosis of diabetes. Raised risk of developing type 2 diabetes, heart disease, and stroke. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Also called impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), depending on the test used to diagnose it. Some people have both IFG and IGT.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;IFG is a condition in which the blood glucose level is high&amp;mdash;100 to 125 mg/dL&amp;mdash;after an overnight fast, but is not high enough to be classified as diabetes. The former definition of IFG was 110 mg/dL to 125 mg/dL. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;IGT is a condition in which the blood glucose level is high&amp;mdash;140 to 199 mg/dL&amp;mdash;after a 2-hour oral glucose tolerance test (OGTT), but is not high enough to be classified as diabetes. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Those with pre-diabetes are likely to develop type 2 diabetes within 10 years, unless they take preventative steps (change in diet and increased physical activity). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;First visit: with primary care physician MD/DO (100%)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The fasting blood glucose test is the preferred test for diagnosing diabetes in children and nonpregnant adults. The test is most reliable when done in the morning. However, a diagnosis of diabetes can be made based on any of the following test results, confirmed by retesting on a different day:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;A blood glucose level of 126 milligrams per deciliter (mg/dL) or higher after an 8-hour fast. This test is called the fasting blood glucose test. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;A blood glucose level of 200 mg/dL or higher 2 hours after drinking a beverage containing 75 grams of glucose dissolved in water. This test is called the oral glucose tolerance test (OGTT). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;A random&amp;mdash;taken at any time of day&amp;mdash;blood glucose level of 200 mg/dL or higher, along with the presence of diabetes symptoms. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Gestational diabetes is diagnosed based on blood glucose levels measured during the OGTT. Glucose levels are normally lower during pregnancy, so the cutoff levels for diagnosis of diabetes in pregnancy are lower. Blood glucose levels are measured before a woman drinks a beverage containing glucose. Then levels are checked 1, 2, and 3 hours afterward. If a woman has two blood glucose levels meeting or exceeding any of the following numbers, she has gestational diabetes: a fasting blood glucose level of 95 mg/dL, a 1-hour level of 180 mg/dL, a 2-hour level of 155 mg/dL, or a 3-hour level of 140 mg/dL. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Possible comorbidities: diabetic neuropathy, heart disease, stroke, obesity, pregnancy (gestational), kidney failure, blindness, hypertension, heart disease, hypoglycemia. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type 1 diabetes&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;5% to 10% of diagnosed diabetics in the United States. Develops most often in children and young adults but can appear at any age. More common in whites than in nonwhites. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Symptoms: increased thirst and urination, constant hunger, weight loss, blurred vision, and extreme fatigue. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If not diagnosed and treated with insulin, a person with type 1 diabetes can lapse into a life-threatening diabetic coma, also known as diabetic ketoacidosis. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type 2 diabetes&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;90% to 95% of people with diabetes have type 2. Most often associated with older age, obesity, family history of diabetes, previous history of gestational diabetes, and physical inactivity. Occurs more often in African Americans, American Indians, some Asian Americans, Native Hawaiians and other Pacific Islander Americans, and Hispanics/Latino. About 80% of people with type 2 diabetes are overweight. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Symptoms: fatigue, frequent urination, increased thirst and hunger, weight loss, blurred vision, and slow healing of wounds or sores, though some people have no symptoms. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;There is a variant of type I diabetes that is adult onset and treated with insulin. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gestational diabetes&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Affects 3% to 8% of pregnant women in the United States. Develops late in pregnancy. Although this form of diabetes usually disappears after the birth of the baby, women who have had gestational diabetes have a 40% to 60% chance of developing type 2 diabetes within 5 to 10 years. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Women with gestational diabetes may not experience any symptoms. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;During the comprehensive medical literature review, preference was given to high quality systematic reviews, meta-analyses, and clinical trials over the past ten years, plus existing nationally recognized treatment guidelines from the leading specialty societies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The heart of each Work Loss Data Institute guideline is the Procedure Summary (see the original guideline document), which provides a concise synopsis of effectiveness, if any, of each treatment method based on existing medical evidence. Each summary and subsequent recommendation is hyper-linked into the studies on which they are based, in abstract form, which have been ranked, highlighted and indexed.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines unite evidence-based protocols for medical treatment with normative expectations for disability duration. They also bridge the interests of the many professional groups involved in diagnosing and treating type 1, type 2, and gestational diabetes.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The benefits of applying bariatric surgery must be weighed against the risk of serious adverse events. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The major side effects of exenatide are gastrointestinal, with nausea and vomiting in some patients. The issue of pancreatitis and pancreatic cancer associated with so-called incretin mimetic therapies for type 2 diabetes has been downplayed by industry, according to a new in-depth investigation by the &lt;em&gt;BMJ&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although the use of intensive vs standard blood pressure targets in patients with type 2 diabetes was associated with a small reduction in the risk for stroke, there was no evidence for decreased mortality or myocardial infarction but an increased risk for hypotension and other adverse events. The annual stroke rates were 0.32% vs 0.53% in the intensive vs standard blood pressure control groups, whereas adverse events such as syncope and dizziness occurred in 1.3% of the standard group compared with 3.3% for the intensive control group. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The addition of premixed insulin to metformin seemed to produce greater reduction in glycosylated hemoglobin (HbA1c) level, slightly greater weight gain, and higher risk for hypoglycemia compared with metformin plus a basal insulin. A case control study suggests that use of antidiabetics such as sulfonylureas and insulin were associated with an increased risk for pancreatic cancer. One analysis found that patients with diabetes who relied on insulin alone faced as much as 4.5 times the estimated risk for pancreatic cancer, as measured in cancer events per 1000 patient years. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One study, which administered the fasting plasma glucose (FPG) test at first prenatal visits, reported that its poor specificity (high false-positive rate) makes it an inefficient screening test for gestational diabetes. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The package insert for commercial, by-prescription-only maggots for debridement therapy warns that pain and discomfort are possible adverse effects, as well as potential allergic reactions in patients who are allergic to fly larvae or the brewer's yeast or soy proteins contained in the nutrient medium that the blowfly eggs are shipped with. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When metformin is used in combination with an insulin secretagogue or insulin, hypoglycemia may occur. Sulfonylureas had a fourfold higher risk for mild or moderate hypoglycemia compared with metformin. This risk increased to fivefold when these types of drugs were used in combination with metformin compared with other combinations. Increased risks for congestive heart failure and bone fractures were observed for thiazolidinediones. Long-term treatment with metformin increases the risk of vitamin B-12 deficiency, which results in raised homocysteine concentrations. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with human immunodeficiency virus (HIV) infection or individuals taking immunosuppressive medications should not undergo leech therapy because of the risk of overwhelming bacterial sepsis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maggot debridement therapy is contraindicated in patients with coagulopathies and in patients with large blood vessels near their wounds. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients with New York Heart Association class III or class IV congestive heart failure, thiazolidinediones are contraindicated. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Treatment Planning section is not designed to be a rule, and therefore should not be used as a basis for Utilization Review. The Treatment Planning section outlines the most common pathways to recovery, but there is no single approach that is right for every patient and these protocols do not mention every treatment that may be recommended. See the Procedure Summaries (in the original guideline document) for complete lists of the various options that may be available, along with links to the medical evidence. The Procedure Summaries are the most important section of Official Disability Guidelines (ODG) Treatment, and that section, not the Treatment Planning section, should be used as a basis for Utilization Review.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Work Loss Data Institute. Diabetes (type 1, 2, and gestational). Encinitas (CA): Work Loss Data Institute; 2013 Sep 5. Various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2013 Sep 5" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Work Loss Data Institute - For Profit Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Work Loss Data Institute&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Editor-in-Chief, Philip L. Denniston, Jr., and Senior Medical Editor, Charles W. Kennedy, Jr., MD, together pilot the group of approximately 80 members. See the ODG &lt;em&gt;Treatment in Workers Comp&lt;/em&gt; &lt;a href=&quot;http://www.worklossdata.com/editorial-advisory-board.html&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Editorial Advisory Board&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;There are no conflicts of interest among the guideline development members.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available to subscribers from the &lt;a title=&quot;Work Loss Data Institute Web site&quot; href=&quot;http://www.odg-disability.com/&quot;&gt;Work Loss Data Institute Web site&lt;/a&gt;.&lt;/p&gt;&#xA;&lt;p&gt;Print copies: Available from the Work Loss Data Institute, 169 Saxony&#xA;Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548,&#xA;760-753-9992, Fax: 760-753-9995; &lt;a title=&quot;Work Loss Data Institute Web site&quot; href=&quot;http://www.worklossdata.com/&quot;&gt;www.worklossdata.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Background &amp;amp; description. Available to subscribers from the &lt;a href=&quot;http://www.odg-twc.com/&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;Work Loss Data Institute (WLDI) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appendix B. ODG Treatment in Workers' Comp. Methodology description using the AGREE instrument. 2014. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.worklossdata.com/uploads/2/4/1/6/24166932/odg_agree_2014.pdf&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;WLDI Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, self-training modules are available from the &lt;a href=&quot;http://www.worklossdata.com/training.html&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;WLDI Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ODG Mobile Pro is available to order from the &lt;a href=&quot;http://www.worklossdata.com/odg-mobile-pro.html&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;WLDI Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appendix C. &lt;em&gt;Official Disability Guidelines (ODG) Treatment in Workers' Comp&lt;/em&gt;. Patient information resources. 2008. Electronic copies: Available to subscribers from the &lt;a href=&quot;http://www.odg-disability.com/&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Work Loss Data Institute Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9992, Fax: 760-753-9995; &lt;a href=&quot;http://www.worklossdata.com/&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;www.worklossdata.com&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI Institute on April 8, 2014. This summary was updated by ECRI Institute on September 15, 2015 following the U.S. Food and Drug Administration (FDA) advisory on DPP-4 Inhibitors for Type 2 Diabetes.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
